FDA Orange Book
Generic for Cancidas
Cancidas contains caspofungin acetate. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Cancidas is caspofungin acetate. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AP.
Run it in Rivvi
Map Cancidas and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Cancidas products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| powder, intravenous | 50MG/VIAL | Discontinued | None | 3 | AP |
| powder, intravenous | 70MG/VIAL | Discontinued | None | 3 | AP |
NDA 021227, held by MERCK AND CO INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic caspofungin acetate
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| GLAND PHARMA LTD | 207092 | AP (A-rated, therapeutically equivalent) | September 29, 2017 | 50MG/VIAL, 70MG/VIAL |
| AREVA PHARMACEUTICALS INC | 211263 | AP (A-rated, therapeutically equivalent) | October 1, 2021 | 50MG/VIAL, 70MG/VIAL |
| HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO LTD | 216506 | AP (A-rated, therapeutically equivalent) | July 18, 2025 | 50MG/VIAL, 70MG/VIAL |
Cancidas NDC codes
Questions
Is there a generic for Cancidas?
Yes. The generic name for Cancidas is caspofungin acetate. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AP.
What is the generic name for Cancidas?
The active ingredient in Cancidas is caspofungin acetate, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.